225 related articles for article (PubMed ID: 16379036)
21. Thyrotropin-secreting pituitary adenoma.
Chang TJ; Chang TC; Lin SM; Huang SF; Pai YH
J Formos Med Assoc; 1998 Dec; 97(12):860-5. PubMed ID: 9884490
[TBL] [Abstract][Full Text] [Related]
22. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
Colao A; Merola B; Ferone D; Marzullo P; Cerbone G; Longobardi S; Di Somma C; Lombardi G
Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
[TBL] [Abstract][Full Text] [Related]
23. Absence of receptors for thyrotropin (TSH)-releasing hormone in human TSH-secreting pituitary adenomas associated with hyperthyroidism.
Chanson P; Li JY; Le Dafniet M; Derome P; Kujas M; Murat A; Charpentier G; Racadot J; Peillon F
J Clin Endocrinol Metab; 1988 Feb; 66(2):447-50. PubMed ID: 2828411
[TBL] [Abstract][Full Text] [Related]
24. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
25. Aberrant expression of thyroid hormone receptor beta isoform may cause inappropriate secretion of TSH in a TSH-secreting pituitary adenoma.
Tagami T; Usui T; Shimatsu A; Beniko M; Yamamoto H; Moriyama K; Naruse M
J Clin Endocrinol Metab; 2011 Jun; 96(6):E948-52. PubMed ID: 21430027
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of patients with thyrotropin-secreting pituitary adenoma.
Wu YY; Chang HY; Lin JD; Chen KW; Huang YY; Jung SM
J Formos Med Assoc; 2003 Mar; 102(3):164-71. PubMed ID: 12783133
[TBL] [Abstract][Full Text] [Related]
27. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genetic characteristics of a large monocentric series of patients affected by thyroid hormone (Th) resistance and suggestions for differential diagnosis in patients without mutation of Th receptor β.
Macchia E; Lombardi M; Raffaelli V; Piaggi P; Macchia L; Scattina I; Martino E
Clin Endocrinol (Oxf); 2014 Dec; 81(6):921-8. PubMed ID: 25040256
[TBL] [Abstract][Full Text] [Related]
29. Thyrotropin-secreting pituitary adenomas: report of seven cases.
Beckers A; Abs R; Mahler C; Vandalem JL; Pirens G; Hennen G; Stevenaert A
J Clin Endocrinol Metab; 1991 Feb; 72(2):477-83. PubMed ID: 1704011
[TBL] [Abstract][Full Text] [Related]
30. [Endocrine abnormalities in a patient with borderline personality disorder--case 8/2014].
Gassenmaier C; Schittenhelm J; Selo N; Schnauder G
Dtsch Med Wochenschr; 2014 Dec; 139(50):2602. PubMed ID: 25474694
[TBL] [Abstract][Full Text] [Related]
31. Differences in response of thyrotropin to 3,5,3'-triiodothyronine and 3,5,3'-triiodothyroacetic acid in patients with resistance to thyroid hormone.
Ueda S; Takamatsu J; Fukata S; Tanaka K; Shimizu N; Sakata S; Yamaji T; Kuma K; Ohsawa N
Thyroid; 1996 Dec; 6(6):563-70. PubMed ID: 9001190
[TBL] [Abstract][Full Text] [Related]
32. A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma.
Poggi M; Monti S; Pascucci C; Toscano V
Am J Med Sci; 2009 Jun; 337(6):462-5. PubMed ID: 19390430
[TBL] [Abstract][Full Text] [Related]
33. A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review.
Yoon JH; Choi W; Park JY; Hong AR; Kim SS; Kim HK; Kang HC
BMC Endocr Disord; 2021 Aug; 21(1):177. PubMed ID: 34461869
[TBL] [Abstract][Full Text] [Related]
34. Thyrotropin expression in hypophyseal pars tuberalis-specific cells is 3,5,3'-triiodothyronine, thyrotropin-releasing hormone, and pit-1 independent.
Bockmann J; Böckers TM; Winter C; Wittkowski W; Winterhoff H; Deufel T; Kreutz MR
Endocrinology; 1997 Mar; 138(3):1019-28. PubMed ID: 9048604
[TBL] [Abstract][Full Text] [Related]
35. Dominant inhibition of thyroid hormone action selectively in the pituitary of thyroid hormone receptor-beta null mice abolishes the regulation of thyrotropin by thyroid hormone.
Abel ED; Moura EG; Ahima RS; Campos-Barros A; Pazos-Moura CC; Boers ME; Kaulbach HC; Forrest D; Wondisford FE
Mol Endocrinol; 2003 Sep; 17(9):1767-76. PubMed ID: 12819298
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism.
Losa M; Mortini P; Minelli R; Giovanelli M
J Endocrinol Invest; 2006 Jun; 29(6):555-9. PubMed ID: 16840835
[TBL] [Abstract][Full Text] [Related]
37. Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma.
Chanson P; Orgiazzi J; Derome PJ; Bression D; Jedynak CP; Trouillas J; Legentil P; Racadot J; Peillon F
J Clin Endocrinol Metab; 1984 Sep; 59(3):542-6. PubMed ID: 6430950
[TBL] [Abstract][Full Text] [Related]
38. TSH secreting pituitary adenoma.
Jha S; Kumar S
J Assoc Physicians India; 2009 Jul; 57():537-9. PubMed ID: 20329419
[TBL] [Abstract][Full Text] [Related]
39. Clinical and morphological characteristics, diagnostic criteria, and outcomes of surgical treatment of TSH-secreting pituitary adenomas.
Astaf'eva LI; Kadashev BA; Shishkina LV; Kalinin PL; Fomichev DV; Kutin MA; Aref'eva IA; Dzeranova LK; Sidneva YG; Klochkova IS; Rotin DL
Zh Vopr Neirokhir Im N N Burdenko; 2016; 80(6):24-35. PubMed ID: 28139570
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
